Name: Sodium Nitrite
Brand: Selleck Chemicals
SKU: S4074
Rating: 5 (1 reviews)

Sodium nitrite is a myeloperoxidase inhibitor with IC50 of 1.3 μM.This product is a hazardous chemical (acute toxicity/flammable/skin corrosive). Please use it while wearing a protective face mask, gloves, and clothing.

Sodium Nitrite Chemical Structure

CAS: 7632-00-0

Purity & Quality Control

Content >99%
Finest quality approved by Nature Medicine
COA
Datasheet
SDS

Sodium Nitrite Related Products

Related Products	Piperlongumine Allopurinol MitoQ (Mitoquinone) mesylate H2DCFDA (DCFH-DA) Disodium (R)-2-Hydroxyglutarate Febuxostat Allopurinol Sodium Neohesperidin Carnosic acid Gallic acid (20R)Ginsenoside Rg3 Pyrogallol Idebenone Hydroquinone (S)-Methylisothiourea sulfate Asiaticoside Sarsasapogenin Troxerutin	Click to Expand
Related Compound Libraries	Kinase Inhibitor Library FDA-approved Drug Library Natural Product Library Bioactive Compound Library-I Bioactive Compound Library-Ⅱ	Click to Expand

Choose Selective ROS Inhibitors

Biological Activity

Description

Sodium nitrite is a myeloperoxidase inhibitor with IC50 of 1.3 μM.This product is a hazardous chemical (acute toxicity/flammable/skin corrosive). Please use it while wearing a protective face mask, gloves, and clothing.

Targets

myeloperoxidase ^[1]

1.3 μM(Kd)

In vitro
In vitro	Sodium nitrite is well known for its role in inhibiting the growth of Clostridium botulinum by inhibiting iron-sulfur clusters essential to energy metabolism. Sodium nitrite slows chlorination by univalently reducing myeloperoxidase to an inactive form and as a consequence is oxidized to nitrogen dioxide. Myeloperoxidase oxidizes free tyrosine to tyrosyl radicals that exchange with tyrosyl residues in peptides. These peptide radicals then couple with nitrogen dioxide to form 3-nitrotyrosyl residues. With neutrophils, myeloperoxidase-dependent nitration required a high concentration of nitrite (1 mM), is doubled by tyrosine, and increases 4-fold by superoxide dismutase. Superoxide is likely to inhibit nitration by reacting with nitrogen dioxide and/or tyrosyl radicals. ^[1] Sodium nitrite results in intoxication of white mice with decrease of red cell superoxide dismutase (SOD) and catalase activity. The total activity of glucose-6-phosphate dehydrogenase and dehydrogenase of 6-phosphogluconate as well as the activity of glutathione reductase are higher in the group of mice that receive sodium nitrite in comparison with the control group. ^[3]
Kinase Assay	H₂O₂ uptake assay
Kinase Assay	Reactions are started by adding 10 nM myeloperoxidase to 30 μM H ₂ O ₂ and varying concentrations of nitrite, in 100 mM phosphate buffer, pH 7.4, containing 20 μM DTPA. Steady state rates of H ₂ O ₂ loss at 21°C are calculated over the first minute. Data are means and ranges of at least duplicate experiments.
Cell Research	Cell lines	Jurkat cells
	Concentrations	~25 μM
	Incubation Time	36 h
	Method	cell density

In Vivo
In vivo	Peak plasma levels of nitrite are achieved in both sexes approximately 30 min after oral exposure. The model predicts that 10% of the hemoglobin is oxidized to the ferric form after oral doses of 15.9 mg/kg in male rats and 11.0 mg/kg in female rats and after intravenous doses of 8.9 and 7.1 mg/kg in male and female rats, respectively. The t_1/2 for recovery from methemoglobinemia is 60 to 120 min depending on dose and route of administration. Replacement of the V_max of methemoglobin reductase with a value representative of humans predicted a 10% methemoglobinemia following an intravenous dose of 5.8 mg/kg, in close agreement with an observed value of 5.7 mg/kg for humans. ^[2]
Animal Research	Animal Models	Twelve-week old Fischer 344 rats
	Dosages	20 mg/kg
	Administration	tail vein injection

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2024-01-11)
NCT04354051	Completed	Cardiovascular Diseases\|Vasodilation\|Hypoxia	University of East Anglia\|Royal Brompton & Harefield NHS Foundation Trust	July 1 2018	Phase 1\|Phase 2
NCT02987088	Completed	Out-Of-Hospital Cardiac Arrest	University of Washington	December 2016	Phase 1
NCT01715883	Terminated	Primary Graft Dysfunction	Gladwin Mark MD\|University of Pittsburgh	October 2011	Phase 2
NCT01316796	Completed	Sickle Cell Anemia\|Sickle Cell Disease\|Chronic Hemolytic Disorders	National Heart Lung and Blood Institute (NHLBI)\|National Institutes of Health Clinical Center (CC)	March 15 2011	Phase 1
NCT00873015	Completed	Subarachnoid Hemorrhage	Hope Pharmaceuticals\|National Institute of Neurological Disorders and Stroke (NINDS)	April 2010	Phase 2
NCT01033227	Terminated	Sickle Cell Disease	Children''s Hospital Los Angeles\|Hope Pharmaceuticals	December 2009	Phase 1\|Phase 2

References

[4] Hammami I, et al. Immunobiology, 2012, 217(8), 808-815.

+ Expand

Chemical Information & Solubility

Molecular Weight	69	Formula	HNO₂.Na
CAS No.	7632-00-0	SDF	Download Sodium Nitrite SDF
Smiles	[Na+].[O-]N=O
Storage (From the date of receipt)	3 years-20°Cpowder	Storage of Stock Solutions Aliquot the stock solutions to avoid repeated freeze-thaw cycles	1 year-80°Cin solvent
Storage (From the date of receipt)	3 years-20°Cpowder		1 month-20°Cin solvent

In vivo
Batch:

Add solvents to the product individually and in order.

In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Dilution Calculator Molecular Weight Calculator

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):